Medical tests

Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With General Services Administration

Retrieved on: 
Wednesday, March 18, 2020
Medicine, Clinical medicine, Medical specialties, Histopathology, Prostate cancer, Medical tests, RTT, Prostate biopsy, Bio-Techne, Biopsy, Exosome, Prostate

MINNEAPOLIS, March 18, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract to its Exosome Diagnostics laboratory, covering the ExoDx Prostate (EPI) test for men.

Key Points: 
  • MINNEAPOLIS, March 18, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract to its Exosome Diagnostics laboratory, covering the ExoDx Prostate (EPI) test for men.
  • Now, approximately 9 million additional men will have access to this non-invasive test for early detection of prostate cancer.
  • It is performed by Exosome Diagnostics, a Bio-Techne brand, in its CLIA, ISO, NY certified and CAP-accredited laboratory located in Waltham, Massachusetts.
  • We need better diagnostic tools, like a prostate carcinoma exosome test, which has the potential to assist in the physician-patient shared decision for prostate biopsy."

Global $2.39 Billion POC Molecular Diagnostics Industry Forecast, 2027 - Key Drivers Include Development of CLIA-Waived Molecular POC Tests, Venture Capital Funding for Development of Products

Retrieved on: 
Tuesday, March 17, 2020
Medicine, Medical tests, Biotechnology, Molecular diagnostics, Branches of biology, Life sciences, POC, Diagnosis

The point of care (POC) molecular diagnostics market is expected to grow at a CAGR of 13.2% from 2019 to 2027 to reach $2.39 billion by 2027.

Key Points: 
  • The point of care (POC) molecular diagnostics market is expected to grow at a CAGR of 13.2% from 2019 to 2027 to reach $2.39 billion by 2027.
  • The growth in the POC molecular diagnostics market is mainly attributed to the rising prevalence of chronic diseases, development of CLIA-waived POC molecular diagnostic tests, venture capital funding for the development of POC molecular diagnostic products, growing demand for POC molecular diagnostics, and need for rapid decision making in emergency care departments.
  • Moreover, emerging countries provide increasing growth opportunities for players operating in the POC molecular diagnostics market.
  • Based on the POC molecular diagnostic products, the kits & assays segment accounted for the largest share of the overall POC molecular diagnostics market in 2019.

Computer Aided Detection- Sharped Vision for Diagnosis: Infinium Global Research

Retrieved on: 
Tuesday, March 17, 2020
Medical imaging, Breast cancer, Medicine, Breast imaging, Cancer screening, Mammography, Projectional radiography, Tomosynthesis, Magnetic resonance imaging, Clinical medicine, Medical tests

Infinium Global Research has recently published a global report on " Computer Aided Detection Market (Application - Oncology, Neurological Disorders, and Cardiovascular Diseases; Imaging Modalities - Nuclear Imaging, Mammography, Ultrasound, Tomosynthesis, Magnetic Resonance Imaging, and Other Imaging Modalities): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025" published by Infinium Global Research", the reported study estimated the market for Computer Aided Detection to reach up to USD 1.2 billion in 2025, with a compound annual growth rate of 10.3%over the forecast period (2019-2025).

Key Points: 
  • Infinium Global Research has recently published a global report on " Computer Aided Detection Market (Application - Oncology, Neurological Disorders, and Cardiovascular Diseases; Imaging Modalities - Nuclear Imaging, Mammography, Ultrasound, Tomosynthesis, Magnetic Resonance Imaging, and Other Imaging Modalities): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025" published by Infinium Global Research", the reported study estimated the market for Computer Aided Detection to reach up to USD 1.2 billion in 2025, with a compound annual growth rate of 10.3%over the forecast period (2019-2025).
  • Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/reports/sample-request/27
    The global computer aided detection market is highly competitive and consolidated in nature.
  • Moreover, the growing adoption of advance technologies and increasing awareness in consumers fuel the growth of computer aided detection market in the region.
  • Furthermore, the Asia Pacific region is anticipated to grow at the fastest rate in the global computer aided detection market.

Roche begins shipments of first 400,000 COVID-19 tests to laboratories across US to begin patient testing under FDA Emergency Use Authorization

Retrieved on: 
Monday, March 16, 2020
Health, Food and Drug Administration, United States Public Health Service, Medical tests, Medicine, Clinical medicine, Medical genetics, Medical diagnosis

"We are grateful to the FDA for accelerating the process to grant Emergency Use Authorization for this test," said Matt Sause, president and CEO of Roche Diagnostics North America.

Key Points: 
  • "We are grateful to the FDA for accelerating the process to grant Emergency Use Authorization for this test," said Matt Sause, president and CEO of Roche Diagnostics North America.
  • "We began shipping test kits immediately so labs could start to offer high-volume testing as soon as possible and give more patients access to reliable diagnostics.
  • The test uses nasopharyngeal or oropharyngeal swab samples (taken from the back of the nose or throat).
  • Healthcare providers across the entire U.S. can send patient samples to these laboratories for processing.

Single-cell Analysis Market by Cell Type, Product, Technique, Application and End User - Global Forecasts to 2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 16, 2020
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Natural sciences, Biology, Laboratory techniques, Cell biology, Clinical pathology, Blood tests, Medical tests, Single-cell analysis, Flow cytometry, Cytometry, Mass spectrometry

The "Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Consumables, Instruments), Technique (Flow Cytometry, NGS, PCR, Mass Spectrometry, Microscopy), Application (Research, Medical Application), End User - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Consumables, Instruments), Technique (Flow Cytometry, NGS, PCR, Mass Spectrometry, Microscopy), Application (Research, Medical Application), End User - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% during the forecast period.
  • Based on the technique, the single-cell analysis market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques.
  • The single-cell analysis market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

INSTANT COLOR CHEMISTRY EXPERT, BAMBU VAULT, IS DEVELOPING RAPID COVID-19 TEST KIT IN RESPONSE TO PRESIDENT TRUMP’S CALL TO ACTION

Retrieved on: 
Thursday, March 12, 2020
Psychometrics, Medical tests, Educational psychology, Sports science, Statistical hypothesis testing, Articles, Tests, Academic disciplines

The BlueAware Dx diagnostic development program is being designed to be a very cost effective, simple and easy-to-use test kit.

Key Points: 
  • The BlueAware Dx diagnostic development program is being designed to be a very cost effective, simple and easy-to-use test kit.
  • The simple test procedure requires an individual to provide a saliva sample into a vial.
  • Should the sample be positive, their unique color change solution will visibly begin to change color in seconds.
  • With additional funding, the company believes that this test can be mass produced and made available in just a few weeks.

Italy In-Vitro Diagnostics Market to 2025 - Analysis, Drivers & Restraints - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 11, 2020
General Health, Other Health, Health, Science, Other Science, Medicine, Clinical medicine, Health, Medical tests, Biotechnology, Medical terminology, Personalized medicine, Companion diagnostic, Chronic condition

The "Italy In-Vitro Diagnostics Market - Growth, Trends & Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Italy In-Vitro Diagnostics Market - Growth, Trends & Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The rising prevalence of chronic disease in Italy has been the primary driver for the growth of this market.
  • Moreover, increasing awareness and acceptance of personalized medicine and companion diagnostics have also helped the market growth.
  • These increasing incidence of diabetes is thus expected to increase the demand for early diagnostics tests, which will help the growth of this market.

Fluidigm and SIgN Establish the First Center of Excellence in Singapore to Advance Imaging Mass Cytometry

Retrieved on: 
Wednesday, March 11, 2020
Branches of biology, Biology, Natural sciences, Cell biology, Flow cytometry, Clinical pathology, Laboratory techniques, Medical tests, Mass cytometry, Cytometry

We are excited about this partnership and committed to harnessing the full power of mass cytometry technology to advance biomarker discovery and accelerate the development of innovative new medicines and diagnostics, said Professor Laurent Renia, Executive Director of SIgN.

Key Points: 
  • We are excited about this partnership and committed to harnessing the full power of mass cytometry technology to advance biomarker discovery and accelerate the development of innovative new medicines and diagnostics, said Professor Laurent Renia, Executive Director of SIgN.
  • As the first CoE for IMC in Singapore and Southeast Asia, the center will focus on single-cell deep spatial immunoprofiling to demonstrate the utility of highly multiplexed imaging across a range of disease areas such as cancer immunology.
  • Using the CoEs dual capabilities of performing both mass cytometry and IMC, researchers will be able to deeply profile a wide range of samples from blood to tissues, all on the same system using highly multiplexed cytometry and tissue imaging.
  • Fluidigm, theFluidigmlogo, CyTOF, Imaging Mass Cytometry, and IMC are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries.

Parallax Diagnostics Announces Intent to Develop a Rapid Screening Test for COVID-19 on its Patented FDA 510(K) Approved Diagnostic Platform

Retrieved on: 
Wednesday, March 11, 2020
Medical tests, Parallax, Vision, Medical terminology, Fields of mathematics, ANGLE, Screening, Measurement, Electromagnetic radiation

Dr. David Stark, President of Parallax Diagnostics, stated, We are seeking partners to accelerate developing a rapid screening test for COVID-19 to meet the urgent demand on a global basis.

Key Points: 
  • Dr. David Stark, President of Parallax Diagnostics, stated, We are seeking partners to accelerate developing a rapid screening test for COVID-19 to meet the urgent demand on a global basis.
  • Dr. Stark went on to say, Parallax is uniquely positioned with its FDA 510(K) approved and patented platform to provide low cost and accurate rapid point of care screening tests within patients in mobile and remote environments.
  • The COVID-19 outbreak is being closely monitored by the Centers for Disease Control (CDC) and the World Health Organization (WHO).
  • Parallax Diagnostics is in discussions with both organizations along with private laboratories and universities to assist in facilitating its participation in providing diagnostic solutions for the creation and deployment of mobile rapid screening tests.

Sepsis Diagnostics Market Size Worth $1.1 Billion by 2027: Grand View Research, Inc.

Retrieved on: 
Wednesday, March 11, 2020
Medical specialties, Medicine, Clinical medicine, Medical tests, Actuarial science, Compound annual growth rate, Mathematical finance, Non-Newtonian calculus, Sepsis, Forecast period, Molecular diagnostics

Key suggestions from the report:

Key Points: 
  • Key suggestions from the report:
    Molecular diagnostics is anticipated to witness a lucrative CAGR over the forecast period owing to its high sensitivity, accuracy, and less turnaround time
    North America dominated the sepsis diagnostics market with the largest revenue share in 2019.
  • High prevalence of HAIs in key regions is expected to significantly increase the demand for medical examination solutions, thereby fueling market growth over the forecast period.
  • Increasing regulatory approval and introduction of technologically advanced medical examination solutions for the life-threatening disease condition are expected to facilitate market growth over the forecast period.
  • Grand View Research has segmented the global sepsis diagnostics market on the basis of product, technology, pathogen, testing type, and region:
    Sepsis Diagnostics Product Outlook (Revenue, USD Million, 2016 - 2027)